LivaNova PLC (NASDAQ:LIVN) Given Average Recommendation of “Hold” by Brokerages

LivaNova PLC (NASDAQ:LIVN) has been assigned a consensus rating of “Hold” from the five analysts that are currently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $64.40.

LIVN has been the topic of a number of analyst reports. Barclays lifted their target price on LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a research report on Monday, February 26th. StockNews.com downgraded shares of LivaNova from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th. Robert W. Baird increased their price objective on shares of LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a research note on Thursday, February 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 price target on shares of LivaNova in a research report on Wednesday, March 20th. Finally, Mizuho restated a “buy” rating and set a $75.00 price objective on shares of LivaNova in a research note on Wednesday, March 27th.

Institutional Trading of LivaNova

Several hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its holdings in shares of LivaNova by 6.4% in the 1st quarter. BlackRock Inc. now owns 7,271,165 shares of the company’s stock worth $316,877,000 after acquiring an additional 436,552 shares during the period. Primecap Management Co. CA raised its position in shares of LivaNova by 7.3% during the 3rd quarter. Primecap Management Co. CA now owns 5,785,360 shares of the company’s stock worth $305,930,000 after buying an additional 395,940 shares in the last quarter. State Street Corp boosted its holdings in shares of LivaNova by 6.8% in the third quarter. State Street Corp now owns 2,556,625 shares of the company’s stock valued at $129,800,000 after acquiring an additional 162,744 shares in the last quarter. Alliancebernstein L.P. raised its holdings in LivaNova by 143.0% during the second quarter. Alliancebernstein L.P. now owns 2,225,363 shares of the company’s stock worth $114,450,000 after purchasing an additional 1,309,486 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in LivaNova by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,770,277 shares of the company’s stock worth $93,612,000 after purchasing an additional 100,133 shares during the period. Institutional investors own 97.64% of the company’s stock.

LivaNova Trading Down 0.8 %

NASDAQ:LIVN opened at $52.33 on Monday. LivaNova has a 12 month low of $42.75 and a 12 month high of $59.86. The business’s 50-day moving average is $53.58 and its two-hundred day moving average is $50.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51. The firm has a market capitalization of $2.82 billion, a PE ratio of 163.54 and a beta of 0.89.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.10. The company had revenue of $310.10 million for the quarter, compared to analyst estimates of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The business’s quarterly revenue was up 12.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.81 earnings per share. Research analysts predict that LivaNova will post 3.01 earnings per share for the current fiscal year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.